<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01705964</url>
  </required_header>
  <id_info>
    <org_study_id>Caperell-Epi-001</org_study_id>
    <nct_id>NCT01705964</nct_id>
  </id_info>
  <brief_title>Intramuscular Epinephrine as an Adjunctive Treatment for Severe Pediatric Asthma Exacerbation</brief_title>
  <official_title>Intramuscular Epinephrine as an Adjunctive Treatment for Severe Pediatric Asthma Exacerbation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Project Aim: To determine if intramuscular epinephrine is an effective adjunct to inhaled&#xD;
      bronchodilators (β2 agonists) for children with severe asthma exacerbation.&#xD;
&#xD;
      Hypothesis: IM epinephrine is an efficacious adjunct to inhaled bronchodilators (β2 agonists)&#xD;
      for children with severe asthma exacerbation.&#xD;
&#xD;
      Intervention: Subjects will be randomly assigned (50% chance) to receive a weight based dose&#xD;
      of IM epinephrine 1:1000 or no adjunctive medication. The dose will be 0.2 mg for subjects&#xD;
      20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by&#xD;
      an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23&#xD;
      gauge one inch needle.&#xD;
&#xD;
      In addition to the study intervention, the standardized treatment pathway based on the&#xD;
      current asthma guidelines in use at the investigator's center will be utilized. This pathway&#xD;
      includes nebulized albuterol, ipratropium bromide, and systemic corticosteroids. The duration&#xD;
      and dosages of these other interventions will be administered at the discretion of the&#xD;
      treating provider.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">April 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Percent of Predicted Peak Expiratory Flow Rate (PEFR) at t15</measure>
    <time_frame>15 minutes after the study intervention</time_frame>
    <description>Change in percent of predicted Peak Expiratory Flow Rate (PEFR) 15 minutes after the study intervention (t15).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disposition</measure>
    <time_frame>At the time a dispostion from the ED is completed (usually within 4 hours of the study intervention)</time_frame>
    <description>Disposition from the ED or rates of discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percent of Predicted PEFR at t120</measure>
    <time_frame>120 minutes after the study intervention</time_frame>
    <description>Change in percent of predicted Peak Expiratory Flow Rate (PEFR) 120 minutes after study intervention compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breaths Per Minute at t120</measure>
    <time_frame>breaths per minute 120 minutes after the study intervention</time_frame>
    <description>breaths per minute at t120 minutes compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate at t120</measure>
    <time_frame>up to 120 minutes after the study intervention</time_frame>
    <description>Heart rate at t120 minutes in beats per minute (BPM)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>IM epinephrine 1:1000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IM epinephrine 1:1000</intervention_name>
    <description>IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.</description>
    <arm_group_label>IM epinephrine 1:1000</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.</description>
    <arm_group_label>No intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age greater than 6 years and less than 18 years&#xD;
&#xD;
          2. Pre-existing diagnosis of asthma&#xD;
&#xD;
          3. Presenting to the ED with an asthma exacerbation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of chronic lung or upper airway disease other than asthma&#xD;
&#xD;
          2. History significant, uncorrected congenital heart disease or cardiac arrhythmia&#xD;
&#xD;
          3. History of thyroid disease&#xD;
&#xD;
          4. Impending respiratory failure&#xD;
&#xD;
          5. Allergy to epinephrine&#xD;
&#xD;
          6. Pregnancy&#xD;
&#xD;
          7. PEFR&gt;60% of predicted and clinical asthma score less than 8&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerry Caperell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kosair Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 9, 2012</study_first_submitted>
  <study_first_submitted_qc>October 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2012</study_first_posted>
  <results_first_submitted>May 6, 2020</results_first_submitted>
  <results_first_submitted_qc>June 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 6, 2021</results_first_posted>
  <last_update_submitted>June 12, 2021</last_update_submitted>
  <last_update_submitted_qc>June 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Kerry Caperell</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Status asthmaticus</keyword>
  <keyword>Asthma exacerbation</keyword>
  <keyword>Epinephrine</keyword>
  <keyword>Adjunctive therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 16, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT01705964/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IM Epinephrine 1:1000</title>
          <description>IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.&#xD;
IM epinephrine 1:1000: IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.</description>
        </group>
        <group group_id="P2">
          <title>No Intervention</title>
          <description>A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.&#xD;
No intervention: A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IM Epinephrine 1:1000</title>
          <description>IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.&#xD;
IM epinephrine 1:1000: IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.</description>
        </group>
        <group group_id="B2">
          <title>No Intervention</title>
          <description>A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.&#xD;
No intervention: A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.00" spread="3.42"/>
                    <measurement group_id="B2" value="10.58" spread="2.76"/>
                    <measurement group_id="B3" value="10.29" spread="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Percent of Predicted Peak Expiratory Flow Rate (PEFR) at t15</title>
        <description>Change in percent of predicted Peak Expiratory Flow Rate (PEFR) 15 minutes after the study intervention (t15).</description>
        <time_frame>15 minutes after the study intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IM Epinephrine 1:1000</title>
            <description>IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.&#xD;
IM epinephrine 1:1000: IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.</description>
          </group>
          <group group_id="O2">
            <title>No Intervention</title>
            <description>A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.&#xD;
No intervention: A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent of Predicted Peak Expiratory Flow Rate (PEFR) at t15</title>
          <description>Change in percent of predicted Peak Expiratory Flow Rate (PEFR) 15 minutes after the study intervention (t15).</description>
          <units>percentage of predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.56" spread="17.11"/>
                    <measurement group_id="O2" value="52.45" spread="13.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disposition</title>
        <description>Disposition from the ED or rates of discharge.</description>
        <time_frame>At the time a dispostion from the ED is completed (usually within 4 hours of the study intervention)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IM Epinephrine 1:1000</title>
            <description>IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.&#xD;
IM epinephrine 1:1000: IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.</description>
          </group>
          <group group_id="O2">
            <title>No Intervention</title>
            <description>A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.&#xD;
No intervention: A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.</description>
          </group>
        </group_list>
        <measure>
          <title>Disposition</title>
          <description>Disposition from the ED or rates of discharge.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percent of Predicted PEFR at t120</title>
        <description>Change in percent of predicted Peak Expiratory Flow Rate (PEFR) 120 minutes after study intervention compared to baseline</description>
        <time_frame>120 minutes after the study intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IM Epinephrine 1:1000</title>
            <description>IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.&#xD;
IM epinephrine 1:1000: IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.</description>
          </group>
          <group group_id="O2">
            <title>No Intervention</title>
            <description>A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.&#xD;
No intervention: A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent of Predicted PEFR at t120</title>
          <description>Change in percent of predicted Peak Expiratory Flow Rate (PEFR) 120 minutes after study intervention compared to baseline</description>
          <units>percentage of PEFR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.51" spread="21.68"/>
                    <measurement group_id="O2" value="56.18" spread="13.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Breaths Per Minute at t120</title>
        <description>breaths per minute at t120 minutes compared to baseline</description>
        <time_frame>breaths per minute 120 minutes after the study intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IM Epinephrine 1:1000</title>
            <description>IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.&#xD;
IM epinephrine 1:1000: IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.</description>
          </group>
          <group group_id="O2">
            <title>No Intervention</title>
            <description>A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.&#xD;
No intervention: A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.</description>
          </group>
        </group_list>
        <measure>
          <title>Breaths Per Minute at t120</title>
          <description>breaths per minute at t120 minutes compared to baseline</description>
          <units>breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.29" spread="5.99"/>
                    <measurement group_id="O2" value="29.29" spread="7.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate at t120</title>
        <description>Heart rate at t120 minutes in beats per minute (BPM)</description>
        <time_frame>up to 120 minutes after the study intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IM Epinephrine 1:1000</title>
            <description>IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.&#xD;
IM epinephrine 1:1000: IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.</description>
          </group>
          <group group_id="O2">
            <title>No Intervention</title>
            <description>A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.&#xD;
No intervention: A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate at t120</title>
          <description>Heart rate at t120 minutes in beats per minute (BPM)</description>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.65" spread="13.91"/>
                    <measurement group_id="O2" value="142.29" spread="16.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years 10 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IM Epinephrine 1:1000</title>
          <description>IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.&#xD;
IM epinephrine 1:1000: IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.</description>
        </group>
        <group group_id="E2">
          <title>No Intervention</title>
          <description>A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.&#xD;
No intervention: A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kerry Caperell</name_or_title>
      <organization>University of Louisville</organization>
      <phone>502-629-7212</phone>
      <email>k0cape01@louisville.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

